Search
Navicixizumab
go.drugbank.com/drugs/DB12634InvestigationalNavicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).
Volenrelaxin
go.drugbank.com/drugs/DB21750InvestigationalVolenrelaxin is under investigation in clinical trial NCT06598631 (Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease).
Medical Cannabis
go.drugbank.com/drugs/DB14009Investigationalwave of legalization in North America has changed public and medical opinion on its use. … In contrast, CB2 receptors are mainly found peripherally in immune cells, lymphoid tissue, and peripheral nerve terminals [A32676].
GALE-301
go.drugbank.com/drugs/DB17262InvestigationalGALE-301 is an investigational cancer immunotherapy. … It is made up of E39, an immunogenic peptide derived from the folate binding protein (FBP), and an immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF).[A254696,L44166,L44171]
Ritodrine
go.drugbank.com/drugs/DB00867ApprovedWithdrawnAdrenergic beta-agonist used to control premature labor.
Chlorprothixene
go.drugbank.com/drugs/DB01239ApprovedInvestigationalWithdrawnChlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.
Tefibazumab
go.drugbank.com/drugs/DB16378InvestigationalTefibazumab is under investigation in clinical trial NCT00198289 (Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs).
Garivulimab
go.drugbank.com/drugs/DB16670InvestigationalGarivulimab is under investigation in clinical trial NCT03379259 (Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors).
Egaptivon pegol
go.drugbank.com/drugs/DB05202InvestigationalEgaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets.
Inlexisertib
go.drugbank.com/drugs/DB21713InvestigationalInlexisertib is under investigation in clinical trial NCT05957367 (A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies). … The usage of the INN stem '-sertib' in the name indicates that Inlexisertib is a serine/threonine kinase inhibitor.